- Male or female >18 years of age at time of enrollment
- Clinical diagnosis of stable plaque type psoriasis
- Two target plaques of similar severity meeting the following criteria:
- 5 cm2 and ≤ 100 cm2, computed by multiplying the greatest diameter of the plaque
by the diameter of the plaque perpendicular to the greatest diameter Bilaterally
located (right/left) plaques on the arms or plaques located on the trunk. Plaques
located on the trunk must be separated by at least 10 cm Overall target plaque
severity score (OTPSS) of 2-4 (mild to moderate) with no more than a 1 point
difference in the scores of the two target plaques
- Willing and able to apply study drug as directed, comply with study instructions and
commit to all follow-up visits
- Ability to understand, agree to and sign the study Informed Consent Form (ICF) prior
to initiation of any protocol related procedures
- Any dermatological conditions, disease state or physical condition that could
interfere with clinical evaluations or might expose the patient to an unacceptable
risk by study participation
- Any underlying disease(s) or other dermatological conditions that require the use of
exclusionary topical or systemic therapy (see below)
- Clinically significant, abnormal Screening laboratory results (unless approved by the
medical monitor)
- Known sensitivity to any of the components of the study medication
- Spontaneously improving or rapidly deteriorating psoriatic plaques or
pustular/exfoliative, guttate, erythrodermic or other non-plaque form of psoriasis
- Concomitant use of topical or systemic therapies that might alter the course of
psoriasis
- Females of child bearing potential. Females must be post-menopausal (based on FSH
levels) or surgically sterile (hysterectomy or bilateral oophorectomy)
- Washout periods for exclusionary therapies:
Oral retinoids: 8 weeks Non-retinoid systemic drugs that might alter the course of
psoriasis: 4 weeks Psoralens with UV-A (PUVA): 4 weeks Ultraviolet-B (UVB) therapy: 4 weeks
Topical drugs that might alter the course of psoriasis: 2 weeks Use of
emollients/moisturizers on area(s) to be treated: 2 days prior to Baseline visit
- AIDS or AIDS-related illness
- Concurrent participation in another drug or device research study or within 30 days
prior to enrollment
- Use of lithium- or hydroxychloroquine-containing products (e.g., Plaquenil)
- Use of a beta-blocking medication (e.g., Propranolol) if the dose has not been
stabilized for at least 3 months
- Use of AN2728 in a previous clinical trial